Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 24 Neoplasms 12 Colonic Neoplasms 12 Breast Neoplasms 12 Prostatic Neoplasms 9 Polycythemia Vera 9 Venous Thromboembolism 8 Multiple Myeloma 8 Recurrence 5 Rectal Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Thrombocythemia, Essential 4 Ovarian Neoplasms 4 Neoplasms, Plasma Cell 4 Neoplasm Metastasis 4 Myeloproliferative Disorders 4 Barrett Esophagus 4 Precancerous Conditions 3 Melanoma 3 Esophageal Neoplasms 3 Adenomatous Polyps 3 Adenoma 3 Tobacco Use Disorder 2 Thrombosis 2 Thromboembolism 2 Smoking Cessation 2 Sarcoma 2 Primary Myelofibrosis 2 Neoplastic Cells, Circulating 2 Neoplasms by Site 2

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 10 aflutinib 9 Drug Therapy 9 Gefitinib 7 Radiotherapy 6 Docetaxel 6 Cisplatin 6 anlotinib 5 Radiosurgery 5 Paclitaxel 5 pembrolizumab 4 Vinorelbine 4 Gemcitabine 4 tislelizumab 3 icotinib 3 apatinib 3 HM781-36B 3 Erlotinib Hydrochloride 3 toripalimab 2 spartalizumab 2 rezivertinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × NSCLC × Aspirin × Clear all

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡